122 related articles for article (PubMed ID: 7248523)
1. Chemical modification of human hemoglobin by antisickling concentrations of nitrogen mustard.
Roth EF; Arnone A; Bookchin RM; Nagel RL
Blood; 1981 Aug; 58(2):300-8. PubMed ID: 7248523
[No Abstract] [Full Text] [Related]
2. Development of antisickling compounds that chemically modify hemoglobin S specifically within the 2,3-diphosphoglycerate binding site.
Walder JA; Walder RY; Arnone A
J Mol Biol; 1980 Aug; 141(2):195-216. PubMed ID: 7441751
[No Abstract] [Full Text] [Related]
3. Alternative diaspirins for modification of hemoglobin and sickle hemoglobin.
Delaney EJ; Massil SE; Shi GY; Klotz IM
Arch Biochem Biophys; 1984 Feb; 228(2):627-38. PubMed ID: 6696450
[TBL] [Abstract][Full Text] [Related]
4. Specific chemical modifications in the beta-cleft site of hemoglobin. Potential anti-sickling agents with hybrid functionalities.
Klotz IM; Haney DN; Wood LE
J Biol Chem; 1985 Dec; 260(30):16215-23. PubMed ID: 4066708
[TBL] [Abstract][Full Text] [Related]
5. Targeted modification of furan-2-carboxaldehydes into Michael acceptor analogs yielded long-acting hemoglobin modulators with dual antisickling activities.
Omar AM; Abdulmalik O; El-Say KM; Ghatge MS; Cyril-Olutayo M; Paredes S; Al-Awadh M; El-Araby ME; Safo MK
Chem Biol Drug Des; 2024 Jan; 103(1):e14371. PubMed ID: 37798397
[TBL] [Abstract][Full Text] [Related]
6. The effect of tris(2-chloroethyl)amine on human hemoglobin.
Albrecht G; Kiese M; Sies H; Weger N
Naunyn Schmiedebergs Arch Pharmacol; 1976 Aug; 294(2):179-85. PubMed ID: 13312
[TBL] [Abstract][Full Text] [Related]
7. Physiological and x-ray studies of potential antisickling agents.
Abraham DJ; Perutz MF; Phillips SE
Proc Natl Acad Sci U S A; 1983 Jan; 80(2):324-8. PubMed ID: 6572894
[TBL] [Abstract][Full Text] [Related]
8. The molecular basis of antisickling agents.
Franklin IM; Huehns ER
Trans R Soc Trop Med Hyg; 1980; 74(6):695-700. PubMed ID: 7210123
[No Abstract] [Full Text] [Related]
9. A Triazole Disulfide Compound Increases the Affinity of Hemoglobin for Oxygen and Reduces the Sickling of Human Sickle Cells.
Nakagawa A; Ferrari M; Schleifer G; Cooper MK; Liu C; Yu B; Berra L; Klings ES; Safo RS; Chen Q; Musayev FN; Safo MK; Abdulmalik O; Bloch DB; Zapol WM
Mol Pharm; 2018 May; 15(5):1954-1963. PubMed ID: 29634905
[TBL] [Abstract][Full Text] [Related]
10. In vitro study of ticlopidine, as a model of antisickling action of platelet antiaggregant.
Sablayrolles M; Wajcman H; Castaigne JP; Labie D
Haematologia (Budap); 1984; 17(2):199-207. PubMed ID: 6534828
[TBL] [Abstract][Full Text] [Related]
11. The alkylation of hemoglobin S by nitrogen mustard. High resolution proton nuclear magnetic resonance studies.
Fung LW; Ho C; Roth EF; Nagel RL
J Biol Chem; 1975 Jun; 250(12):4786-9. PubMed ID: 1141230
[TBL] [Abstract][Full Text] [Related]
12. A view of the current status of antisickling therapy.
Brewer GJ
Am J Hematol; 1976; 1(1):121-8. PubMed ID: 790948
[No Abstract] [Full Text] [Related]
13. Diaspirins of methylenecitric acid.
Massil SE; Shi GY; Klotz IM
J Pharm Sci; 1984 Mar; 73(3):418-20. PubMed ID: 6716258
[TBL] [Abstract][Full Text] [Related]
14. Thermodynamics of anti-sickling agents with hemoglobin S.
Benedict RC; Richey B; Fall L; Gill SJ; Nagel RL; Wyman J
J Mol Biol; 1981 Aug; 150(3):423-34. PubMed ID: 7299823
[No Abstract] [Full Text] [Related]
15. Aryloxyalkanoic Acids as Non-Covalent Modifiers of the Allosteric Properties of Hemoglobin.
Omar AM; Mahran MA; Ghatge MS; Bamane FH; Ahmed MH; El-Araby ME; Abdulmalik O; Safo MK
Molecules; 2016 Aug; 21(8):. PubMed ID: 27529207
[TBL] [Abstract][Full Text] [Related]
16. The binding of hemoglobin to membranes of normal and sickle erythrocytes.
Fischer S; Nagel RL; Bookchin RM; Roth EF; Tellez-Nagel I
Biochim Biophys Acta; 1975 Feb; 375(3):422-33. PubMed ID: 235288
[TBL] [Abstract][Full Text] [Related]
17. Use of citrate agar electrophoresis in evaluation of antisickling agents.
Wilson E; Winter WP
J Natl Med Assoc; 1981 Feb; 73(2):111-6. PubMed ID: 7205973
[TBL] [Abstract][Full Text] [Related]
18. Rational design of pyridyl derivatives of vanillin for the treatment of sickle cell disease.
Pagare PP; Ghatge MS; Musayev FN; Deshpande TM; Chen Q; Braxton C; Kim S; Venitz J; Zhang Y; Abdulmalik O; Safo MK
Bioorg Med Chem; 2018 May; 26(9):2530-2538. PubMed ID: 29655608
[TBL] [Abstract][Full Text] [Related]
19. Structural basis for the potent antisickling effect of a novel class of five-membered heterocyclic aldehydic compounds.
Safo MK; Abdulmalik O; Danso-Danquah R; Burnett JC; Nokuri S; Joshi GS; Musayev FN; Asakura T; Abraham DJ
J Med Chem; 2004 Sep; 47(19):4665-76. PubMed ID: 15341482
[TBL] [Abstract][Full Text] [Related]
20. Effect of cetiedil on erythrocyte sickling: new type of antisickling agent that may affect erythrocyte membranes.
Asakura T; Ohnishi ST; Adachi K; Ozguc M; Hashimoto K; Singer M; Russell MO; Schwartz E
Proc Natl Acad Sci U S A; 1980 May; 77(5):2955-9. PubMed ID: 6930678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
